Access the full text.
Sign up today, get DeepDyve free for 14 days.
L. Bonetta (2009)
RNA-Based Therapeutics: Ready for Delivery?Cell, 136
A. Malek, E. Bakhidze, A. Noske, C. Sers, A. Aigner, R. Schäfer, O. Tchernitsa (2008)
HMGA2 gene is a promising target for ovarian cancer silencing therapyInternational Journal of Cancer, 123
J. DeVincenzo, Rob Lambkin-Williams, T. Wilkinson, J. Cehelsky, S. Nochur, E. Walsh, R. Meyers, J. Gollob, A. Vaishnaw (2010)
A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virusProceedings of the National Academy of Sciences, 107
G. Regis, L. Icardi, Laura Conti, Roberto Chiarle, Roberto Piva, M. Giovarelli, Valeria Poli, Francesco Novelli (2009)
IL-6, but not IFN-γ, triggers apoptosis and inhibits in vivo growth of human malignant T cells on STAT3 silencingLeukemia, 23
Xiao-wen He, Xiao Yu, Ting Liu, Shibin Yu, Dao-jin Chen (2008)
Vector-based RNA interference against vascular endothelial growth factor-C inhibits tumor lymphangiogenesis and growth of colorectal cancer in vivo in mice.Chinese medical journal, 121 5
R. Natarajan, Fadi Salloum, B. Fisher, Evan Ownby, R. Kukreja, A. Fowler (2007)
Activation of hypoxia-inducible factor-1 via prolyl-4 hydoxylase-2 gene silencing attenuates acute inflammatory responses in postischemic myocardium.American journal of physiology. Heart and circulatory physiology, 293 3
Xin-ling Ren, Yan-ming Xu, W. Bao, Hai-jing Fu, Chang‐gui Wu, Ying Zhao, Zhi-kui Li, Jian Zhang, Sheng-Qing Li, Wei-qiang Chen, Tao Wang, Rui Zhang, Li-hong Zhang, G. Qian, Si-Yi Chen, L. Jia, A. Yang (2009)
Inhibition of non-small cell lung cancer cell proliferation and tumor growth by vector-based small interfering RNAs targeting HER2/neu.Cancer letters, 281 2
J. Kaufmann, K. Ahrens, A. Santel (2010)
RNA interference for therapy in the vascular endothelium.Microvascular research, 80 2
S. Singhal, Cherice Roth, Kathryn Leake, J. Singhal, Sushma Yadav, S. Awasthi (2009)
Regression of prostate cancer xenografts by RLIP76 depletion.Biochemical pharmacology, 77 6
F. Kamlah, B. Eul, Shu Li, N. Lang, L. Marsh, W. Seeger, F. Grimminger, F. Rose, J. Hänze (2009)
Intravenous injection of siRNA directed against hypoxia-inducible factors prolongs survival in a Lewis lung carcinoma cancer modelCancer Gene Therapy, 16
Sun Kim, J. Jeong, Soo Lee, S. Kim, T. Park (2008)
Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer.Journal of controlled release : official journal of the Controlled Release Society, 129 2
S. Akhtar, I. Benter (2007)
Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity.Advanced drug delivery reviews, 59 2-3
Olivia Merkel, D. Librizzi, A. Pfestroff, T. Schurrat, M. Béhé, T. Kissel (2009)
In vivo SPECT and real-time gamma camera imaging of biodistribution and pharmacokinetics of siRNA delivery using an optimized radiolabeling and purification procedure.Bioconjugate chemistry, 20 1
Sateesh Kunigal, S. Lakka, Prasanna Sodadasu, Norman Estes, J. Rao (2009)
Stat3-siRNA induces Fas-mediated apoptosis in vitro and in vivo in breast cancer.International journal of oncology, 34 5
Feng Wang, Lin Chen, Zhen-biao Mao, J. Shao, Chang Tan, W. Huang (2008)
Lentivirus-mediated short hairpin RNA targeting the APRIL gene suppresses the growth of pancreatic cancer cells in vitro and in vivo.Oncology reports, 20 1
Weici Zhang, Yongyan Chen, Haiming Wei, C. Zheng, R. Sun, Jian Zhang, Z. Tian (2008)
Antiapoptotic Activity of Autocrine Interleukin-22 and Therapeutic Effects of Interleukin-22-Small Interfering RNA on Human Lung Cancer XenograftsClinical Cancer Research, 14
H. Hlawaty, A. Juan, M. Jacob, R. Vranckx, D. Letourneur, L. Feldman (2007)
Inhibition of MMP-2 gene expression with small interfering RNA in rabbit vascular smooth muscle cells.American journal of physiology. Heart and circulatory physiology, 293 6
R. Álvarez, Sayda Elbashir, T. Borland, I. Toudjarska, P. Hadwiger, M. John, I. Roehl, Svetlana Morskaya, R. Martinello, J. Kahn, M. Ranst, R. Tripp, J. DeVincenzo, R. Pandey, M. Maier, L. Nechev, M. Manoharan, V. Kotelianski, R. Meyers (2009)
RNA Interference-Mediated Silencing of the Respiratory Syncytial Virus Nucleocapsid Defines a Potent Antiviral StrategyAntimicrobial Agents and Chemotherapy, 53
Mouchun Gong, Zheng-mao Lu, Guo-en Fang, J. Bi, Xuchao Xue (2008)
A small interfering RNA targeting osteopontin as gastric cancer therapeutics.Cancer letters, 272 1
Heehyoung Lee, S. Pal, K. Reckamp, R. Figlin, Hua Yu (2011)
STAT3: a target to enhance antitumor immune response.Current topics in microbiology and immunology, 344
Qing-quan Li, Jing-da Xu, Wen-juan Wang, Xi-xi Cao, Qi Chen, F. Tang, Zhong-qing Chen, Xiu-Ping Liu, Zu-de Xu (2009)
Twist1-Mediated Adriamycin-Induced Epithelial-Mesenchymal Transition Relates to Multidrug Resistance and Invasive Potential in Breast Cancer CellsClinical Cancer Research, 15
Chang Tan, Baoqin Xuan, Jie Hong, Zhaoyun Dai, Ruixin Hao, Zhengwu Li, Weida Huang (2007)
RNA interference against hepatitis B virus with endoribonuclease-prepared siRNA despite of the target sequence variations.Virus research, 126 1-2
N. Sakamoto, Y. Tanabe, T. Yokota, Kenichi Satoh, Yuko Sekine‐Osajima, M. Nakagawa, Yasuhiro Itsui, M. Tasaka, Y. Sakurai, Chen Cheng-Hsin, M. Yano, S. Ohkoshi, Y. Aoyagi, S. Maekawa, N. Enomoto, M. Kohara, Mamoru Watanabe (2007)
Inhibition of hepatitis C virus infection and expression in vitro and in vivo by recombinant adenovirus expressing short hairpin RNAJournal of Gastroenterology and Hepatology, 23
Chun‐fang Xia, R. Boado, W. Pardridge (2009)
Antibody-mediated targeting of siRNA via the human insulin receptor using avidin-biotin technology.Molecular pharmaceutics, 6 3
Xiaohua Shi, Zhiyong Liang, X. Ren, Tong-hua Liu (2009)
Combined silencing of K-ras and Akt2 oncogenes achieves synergistic effects in inhibiting pancreatic cancer cell growth in vitro and in vivoCancer Gene Therapy, 16
H. Tang, Jun Wang, F. Bai, L. Hong, Jie Liang, Juan Gao, Hui-hong Zhai, M. Lan, Faming Zhang, Kaichun Wu, D. Fan (2007)
Inhibition of osteopontin would suppress angiogenesis in gastric cancer.Biochemistry and cell biology = Biochimie et biologie cellulaire, 85 1
K. Iwaki, K. Shibata, M. Ohta, Y. Endo, H. Uchida, Masayuki Tominaga, Ryoki Okunaga, S. Kai, S. Kitano (2008)
A small interfering RNA targeting proteinase‐activated receptor‐2 is effective in suppression of tumor growth in a Panc1 xenograft modelInternational Journal of Cancer, 122
A. Veeravagu, A. Hsu, W. Cai, Lewis Hou, V. Tse, Xiaoyuan Chen (2007)
Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.Recent patents on anti-cancer drug discovery, 2 1
Xuan Song, Jiabei Wang, Dalong Yin, Haiyan Yang, Lian-Xin Liu, Hong-chi Jiang (2009)
Down-regulation of lung resistance related protein by RNA interference targeting survivin induces the reversal of chemoresistances in hepatocellular carcinoma.Chinese medical journal, 122 21
Jennifer Podesta, K. Al‐Jamal, M. Herrero, Bowen Tian, H. Ali-Boucetta, V. Hegde, A. Bianco, M. Prato, Kostas Kostarelos (2009)
Antitumor activity and prolonged survival by carbon-nanotube-mediated therapeutic siRNA silencing in a human lung xenograft model.Small, 5 10
M. Behlke (2008)
Chemical modification of siRNAs for in vivo use.Oligonucleotides, 18 4
Maria Mikhaylova, Ioannis Stasinopoulos, Yoshinori Kato, D. Artemov, Z. Bhujwalla (2009)
Imaging of cationic multifunctional liposome-mediated delivery of COX-2 siRNACancer Gene Therapy, 16
Tao Chen, Chang-sheng Deng (2008)
Inhibitory effect of siRNA targeting survivin in gastric cancer MGC-803 cells.International immunopharmacology, 8 7
Y. Dai, L. Qiao, K. Chan, Mo Yang, J. Ye, Rongxin Zhang, Juan Ma, B. Zou, C. Lam, Jide Wang, R. Pang, V. Tan, H. Lan, B. Wong (2009)
Adenovirus-mediated down-regulation of X-linked inhibitor of apoptosis protein inhibits colon cancerMolecular Cancer Therapeutics, 8
A. Aigner (2007)
Applications of RNA interference: current state and prospects for siRNA-based strategies in vivoApplied Microbiology and Biotechnology, 76
Martin Meyer, C. Dohmen, Alexander Philipp, D. Kiener, Gelja Maiwald, C. Scheu, M. Ogris, E. Wagner (2009)
Synthesis and biological evaluation of a bioresponsive and endosomolytic siRNA-polymer conjugate.Molecular pharmaceutics, 6 3
Xiufen Zheng, C. Vladau, Xusheng Zhang, Motohiko Suzuki, T. Ichim, Zhu-Xu Zhang, Mu Li, E. Carrier, B. Garcia, A. Jevnikar, W. Min (2009)
A novel in vivo siRNA delivery system specifically targeting dendritic cells and silencing CD40 genes for immunomodulation.Blood, 113 12
D. Kunze, D. Wuttig, I. Kausch, C. Blietz, L. Blumhoff, Y. Burmeister, K. Kraemer, S. Fuessel, M. Toma, B. Schwenzer, A. Meye, M. Grimm, O. Hakenberg, D. Jocham, M. Wirth (2008)
Antisense-mediated inhibition of survivin, hTERT and VEGF in bladder cancer cells in vitro and in vivo.International journal of oncology, 32 5
Jian-jun Shen, Jiayun Liu, Y. Long, Y. Miao, M. Su, Qing Zhang, Hua Han, X. Hao (2009)
Knockdown of survivin expression by siRNAs enhances chemosensitivity of prostate cancer cells and attenuates its tumorigenicity.Acta biochimica et biophysica Sinica, 41 3
S. Leachman, R. Hickerson, M. Schwartz, Emily Bullough, S. Hutcherson, K. Boucher, C. Hansen, Mark Eliason, G. Srivatsa, D. Kornbrust, Frances Smith, W. McLean, L. Milstone, R. Kaspar (2010)
First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder.Molecular therapy : the journal of the American Society of Gene Therapy, 18 2
S. Réjiba, Christelle Bigand, C. Parmentier, A. Hajri (2009)
Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies.Neoplasia, 11 7
B. Ryan, N. O'Donovan, M. Duffy (2009)
Survivin: a new target for anti-cancer therapy.Cancer treatment reviews, 35 7
A. Malek, Olivia Merkel, L. Fink, F. Czubayko, T. Kissel, A. Aigner (2009)
In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes.Toxicology and applied pharmacology, 236 1
H. Fechner, I. Sipo, D. Westermann, S. Pinkert, Xiaomin Wang, L. Suckau, J. Kurreck, H. Zeichhardt, O. Müller, R. Vetter, V. Erdmann, C. Tschope, W. Poller (2008)
Cardiac-targeted RNA interference mediated by an AAV9 vector improves cardiac function in coxsackievirus B3 cardiomyopathyJournal of Molecular Medicine, 86
Padmaja Tummalapalli, C. Gondi, D. Dinh, M. Gujrati, J. Rao (2007)
RNA interference-mediated targeting of urokinase plasminogen activator receptor and matrix metalloproteinase-9 gene expression in the IOMM-lee malignant meningioma cell line inhibits tumor growth, tumor cell invasion and angiogenesis.International journal of oncology, 31 1
W. Shen, Chun-yi Wang, Xue-hu Wang, Z. Fu (2009)
Oncolytic adenovirus mediated Survivin knockdown by RNA interference suppresses human colorectal carcinoma growth in vitro and in vivoJournal of Experimental & Clinical Cancer Research : CR, 28
Lisa Moss, Mandy Starbuck, D. Mayer, E. Harwood, J. Glotzer (2009)
Trastuzumab-induced cardiotoxicity.Oncology nursing forum, 36 6
Sateesh Kunigal, S. Lakka, C. Gondi, Norman Estes, J. Rao (2007)
RNAi‐mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease‐9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growthInternational Journal of Cancer, 121
N. Hokaiwado, F. Takeshita, A. Banaś, T. Ochiya (2008)
RNAi-based drug discovery and its application to therapeutics.IDrugs : the investigational drugs journal, 11 4
H. Hlawaty, A. Juan, M. Jacob, R. Vranckx, D. Letourneur, L. Feldman (2009)
Local matrix metalloproteinase 2 gene knockdown in balloon‐injured rabbit carotid arteries using nonviral‐small interfering RNA transfectionThe Journal of Gene Medicine, 11
Padmaja Tummalapalli, Daniel Spomar, C. Gondi, W. Olivero, M. Gujrati, D. Dinh, J. Rao (2007)
RNAi-mediated abrogation of cathepsin B and MMP-9 gene expression in a malignant meningioma cell line leads to decreased tumor growth, invasion and angiogenesis.International journal of oncology, 31 5
S. Ohri, A. Vashishta, M. Proctor, M. Fusek, V. Vetvicka (2007)
Depletion of procathepsin D gene expression by RNA interference – A potential therapeutic target for breast cancerCancer Biology & Therapy, 6
Leying Zhang, D. Alizadeh, Michelle Handel, M. Kortylewski, Hua Yu, B. Badie (2009)
Stat3 inhibition activates tumor macrophages and abrogates glioma growth in miceGlia, 57
P. Kaiser, R. Symons, S. Shah, E. Quinlan, H. Tabandeh, D. Do, Gail Reisen, Jennifer Lockridge, B. Short, R. Guerciolini, Q. Nguyen, Sirna Investigators (2010)
RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027.American journal of ophthalmology, 150 1
L. Mangala, H. Han, G. Lopez-Berestein, A. Sood (2009)
Liposomal siRNA for ovarian cancer.Methods in molecular biology, 555
Michael Gray, N. Dallas, G. Buren, L. Xia, A. Yang, R. Somcio, P. Gaur, L. Mangala, P. Vivas-Mejia, F. Fan, A. Sanguino, G. Gallick, G. Lopez-Berestein, Anil Sood, L. Ellis (2008)
Therapeutic targeting of Id2 reduces growth of human colorectal carcinoma in the murine liverOncogene, 27
Eur J Clin Invest 2011; 41 (2): 221–232 Background RNA interference (RNAi) has become the method of choice for researchers wishing to target specific genes for silencing and has provided immense potential as therapeutic tools. This narrative review article aimed to understand potential benefits and limitations of RNAi technique for clinical application and in vivo studies through reading the articles published during the recent 3 years. Materials and methods Medline database was searched by using ‘siRNA’ or ‘RNAi’ and ‘in vivo’ with limits of dates ‘published in the last 3 years’, language ‘English’ and article type ‘clinical trial’ for obtaining articles on in vivo studies on the use of RNAi technique. Characteristics of clinical trials on siRNA registered at the http://www.ClinicalTrials.gov were analysed. Results The only three clinical studies published so far and many in vivo studies in animals showed that the RNAi technique is safe and effective in treatment of cancers of many organ/systems and various other diseases including viral infection, arterial restenosis and some hereditary diseases with considerable benefits such as high specificity, many possible routes of administration and possibility of silencing multiple genes at the same time. Limitations and uncertainty include efficiency of cellular uptake, specific guidance to the target tissue or cell, long‐term safety, sustained efficacy and rapid clearance from the body. Conclusions RNAi technique will become an important and potent weapon for fighting against various diseases. RNAi technique has benefits and limitations in its potential clinical applications. Overcoming the obstacles is still a formidable task.
European Journal of Clinical Investigation – Wiley
Published: Feb 1, 2011
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.